Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isoferulic acid alleviates LPS/D-galactosamine-induced acute liver injury in mice by inhibiting ERK/NF-κB signaling and modulating the NLRP3 inflammasome.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

Variability in epilepsy polygenic risk prediction across Taiwanese population and clinical cohorts.

Epilepsia·2026
Same author

Correction to: Differential striatal dopamine binding in Parkinson's Disease with and without REM sleep behavior disorder: A Tc‑99 m TRODAT‑1 SPECT study.

GeroScience·2026
Same author

Therapeutic effects of 40 Hz light stimulation on clinical and pathological features of Alzheimer's disease.

Dialogues in clinical neuroscience·2026
Same author

Development and Validation of a Machine Learning-Based Dementia Screening Tool: The Six-Question Dementia Screening Test.

American journal of Alzheimer's disease and other dementias·2026
Same author

Using Plasma Amyloid Beta Oligomer to Screen in Alzheimer's Disease: A Pilot Study.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Yuan-Han Yang1,2,3, Ling-Chun Huang1, Ching-Fang Chien4

  • 1Kaohsiung Medical University Gangshan Hospital, Kaohsiung, Taiwan.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

This pilot study suggests that 40 Hz gamma light therapy may alter Alzheimer's disease (AD) biomarkers in plasma. Further large-scale studies are needed to confirm these findings for AD treatment.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neurology
  • Biomarker Research
  • Light Therapy

Background:

  • Previous research indicates 40 Hz gamma light therapy may slow clinical decline in Alzheimer's Disease (AD) patients.
  • Cell-line studies suggest gamma light reduces tau protein phosphorylation and beta-amyloid aggregation.
  • Plasma biomarkers like Aβ40/Aβ42 ratio, p-tau181, and p-tau217 are emerging indicators of cerebral amyloid and tau burden.

Purpose of the Study:

  • To investigate if 40 Hz gamma light intervention can modify plasma biomarkers in AD patients.
  • To assess the impact of gamma light therapy on both psychometric measures and plasma biomarkers.

Main Methods:

  • Seven clinically diagnosed AD patients received daily 1-hour home-based 40 Hz gamma light therapy for six months.
  • Neuropsychological assessments (MMSE, CASI, CDR, NPI) and blood samples were collected at baseline and six months.
  • Plasma levels of Aβ40, Aβ42, p-tau181, and p-tau217 were quantified using ELISA.

Main Results:

  • No significant psychometric improvements were observed due to the limited sample size.
  • However, plasma p-tau181 levels did not increase in 5 out of 7 patients post-intervention.
  • Plasma p-tau217 levels also remained stable in 6 out of 7 patients after the light therapy.

Conclusions:

  • This pilot study provides preliminary evidence that 40 Hz light intervention can modify AD-related plasma biomarkers.
  • Larger randomized controlled trials are warranted to validate these findings and explore clinical efficacy.